Travoprost

Highest phase reached

Approved

www.ebi.ac.uk

Drug type

Small molecule

www.ebi.ac.uk

First approval year

2001

www.ebi.ac.uk

First approval year: 2001
www.ebi.ac.uk

Listing at source: Listed

Highest phase reached: Approved
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Travoprost
www.ebi.ac.uk

Molecular weight: 500.55
www.ebi.ac.uk

Structure (SMILES): CC(C)OC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)COc2cccc(C(F)(F)F)c2)[C@H](O)C[C@@H]1O
www.ebi.ac.uk

idose tr
Idose tr
izba
Izba
travatan
Travatan
travatan z
Travatan z
travoprost
Travoprost
travoprost component of duotrav
Travoprost component of duotrav

(1R-(1.ALPHA.(Z),2.BETA.(1E,3R*),3.ALPHA.,5.ALPHA.))-7-(3,5-DIHYDROXY-2-(3-HYDROXY-4-(3-(TRIFLUOROMETHYL)PHENOXY)-1-BUTENYL)CYCLOPENTYL)-5-HEPTENOIC ACID, 1-METHYLETHYL ESTER
1r 1 alpha z 2 beta 1e 3r 3 alpha 5 alpha 7 3 5 dihydroxy 2 3 hydroxy 4 3 trifluoromethyl phenoxy 1 butenyl cyclopentyl 5 heptenoic acid 1 methylethyl ester
al 6221
AL-6221
DuoTrav (travoprost-timolol ophthalmic drops)
duotrav component travoprost
DUOTRAV COMPONENT TRAVOPROST
duotrav travoprost timolol ophthalmic drops
idose tr
iDose TR
Idose tr
iDose TR (travoprost intracameral implant) 75 µg
iDose TR (travoprost intracameral implant) 75 μg in conjunction
iDose TR (Travoprost intracameral Implant) 75mcg
idose tr travoprost intracameral implant 75 µg
idose tr travoprost intracameral implant 75 μg in conjunction
idose tr travoprost intracameral implant 75mcg
latanoprost bimatoprost travoprost
nsc 760366
NSC-760366
otx tp
Otx-tp
OTX-TP
topical travoprost
Topical travoprost

And 48 more, listed on the interactive page.

ATC classification codes

S01EE04

Sources for recorded values

www.ebi.ac.uk

CAS registry numbers

157283-68-6

ChEMBL ID: CHEMBL1200799
www.ebi.ac.uk

InChIKey: MKPLKVHSHYCHOC-AHTXBMBWSA-N
www.ebi.ac.uk

PubChem compound IDs

5282226

RxNorm IDs (RxCUI)

283809

FDA ingredient codes (UNII)

WJ68R08KX9

Applicant: SANDOZ
Approval date: 21 Sept 2006
Application number: NDA021994

Status: Authorised
Status date: 27 Nov 2001
Authorisation date: 27 Nov 2001
Approved indications: Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).
Product number: EMEA/H/C/000390
Authorisation holder: Novartis Europharm Limited
Priority medicines scheme: No
Generic: No
Biosimilar: No
Generic medicines: 0
Biosimilar medicines: 0
Advanced therapy: No
Conditional approval: No
Additional monitoring: No
Accelerated assessment: No
Exceptional circumstances: No

Therapeutic areas

Glaucoma, Open-Angle
Ocular Hypertension

European medicines record

www.ema.europa.eu

Patents: 11
Designations: 1
Earliest recorded loss of exclusivity: 14 Feb 2031
First in class: No
Fast track: No
Breakthrough designation: No
Orphan designation: No
Priority review: Yes
Orphan exclusivity: No
Accelerated approval: No
Availability: Prescription only

United States (FDA): Approved
European Union (EMA): Authorised

Pharmacology name: travoprost
Type: Synthetic organic
Drug name stem: -prost
Approval recorded by Guide to Pharmacology: Yes

Administration routes

topical

Mechanisms of action

Mechanism
Prostanoid FP receptor agonist
Action type
Agonist
Target
Prostaglandin F2-alpha receptor
Protein identifier
P43088

Open Targets mechanisms

Mechanism
Prostanoid FP receptor agonist
Action type
Agonist
Target
Prostaglandin F2-alpha receptor

DrugCentral mechanisms

Action type
Agonist
Gene symbol
PTGFR
Protein identifier
P43088
Organism
Homo sapiens
Target development level
Clinical

Condition
Glaucoma, Open-Angle
Highest recorded phase
4
Condition identifier
EFO:0004190
Subject identifier
D005902
Condition
Exfoliation Syndrome
Highest recorded phase
3
Condition identifier
EFO:0004235
Subject identifier
D017889
Condition
Ocular Hypertension
Highest recorded phase
4
Condition identifier
EFO:1001069
Subject identifier
D009798
Condition
Glaucoma
Highest recorded phase
4
Condition identifier
MONDO:0005041
Subject identifier
D005901

Condition identifier
EFO_0004190
Condition identifier
EFO_0004235
Highest recorded phase
3
Condition identifier
EFO_1001060
Condition identifier
EFO_1001069
Condition identifier
HP_0000737
Condition identifier
MONDO_0001868
Highest recorded phase
3
Condition identifier
MONDO_0001966
Highest recorded phase
3
Condition identifier
MONDO_0005041
Condition identifier
MONDO_0005041
Highest recorded phase
4
Condition identifier
MONDO_0005338
Highest recorded phase
4
Condition identifier
MONDO_0006875
Highest recorded phase
4
Condition identifier
MONDO_0008327
Condition identifier
MONDO_0019783

Event
abnormal sensation in eye
Reports
7
Reporting signal score
15.9262
Event
asthenia
Reports
7
Reporting signal score
14.3899
Event
blepharal pigmentation
Reports
4
Reporting signal score
16.4762
Event
blepharitis
Reports
11
Reporting signal score
27.8035
Event
blindness
Reports
31
Reporting signal score
44.003
Event
blindness unilateral
Reports
12
Reporting signal score
18.9656
Event
blood immunoglobulin e increased
Reports
8
Reporting signal score
19.4267
Event
choroidal detachment
Reports
6
Reporting signal score
18.5258
Event
choroidal effusion
Reports
7
Reporting signal score
21.0157
Event
conjunctival hyperaemia
Reports
11
Reporting signal score
24.1213
Event
conjunctival oedema
Reports
6
Reporting signal score
16.3521
Event
conjunctivitis allergic
Reports
6
Reporting signal score
16.7507
Event
corneal disorder
Reports
7
Reporting signal score
16.6124
Event
corneal oedema
Reports
9
Reporting signal score
20.2777
Event
cystoid macular oedema
Reports
10
Reporting signal score
25.7938
Event
dark circles under eyes
Reports
7
Reporting signal score
24.7617
Event
diarrhoea
Reports
11
Reporting signal score
28.6982
Event
dry eye
Reports
37
Reporting signal score
64.9464
Event
erythema of eyelid
Reports
12
Reporting signal score
30.1926
Event
eye allergy
Reports
15
Reporting signal score
64.4427
Event
eye disorder
Reports
22
Reporting signal score
32.4215
Event
eye inflammation
Reports
16
Reporting signal score
35.3418
Event
eye irritation
Reports
141
Reporting signal score
439.515
Event
eye pain
Reports
74
Reporting signal score
168.233
Event
eye pruritus
Reports
44
Reporting signal score
100.807

And 36 more, listed on the interactive page.

NCT00051142
clinicaltrials.gov
NCT00051155
clinicaltrials.gov
NCT00051168
clinicaltrials.gov
NCT00051181
clinicaltrials.gov
NCT00288951
clinicaltrials.gov
NCT00293761
clinicaltrials.gov
NCT00293787
clinicaltrials.gov
NCT00293800
clinicaltrials.gov
NCT00311389
clinicaltrials.gov
NCT00333125
clinicaltrials.gov
NCT00767494
clinicaltrials.gov
NCT01452009
clinicaltrials.gov
NCT01453855
clinicaltrials.gov
NCT01464424
clinicaltrials.gov
NCT01652664
clinicaltrials.gov
NCT01655758
clinicaltrials.gov
NCT00308945
clinicaltrials.gov
NCT00331240
clinicaltrials.gov
NCT01443988
clinicaltrials.gov
NCT01444040
clinicaltrials.gov
NCT02754596
clinicaltrials.gov
NCT02873806
clinicaltrials.gov
NCT03966560
clinicaltrials.gov
NCT04615403
clinicaltrials.gov
NCT06066645
clinicaltrials.gov

And 19 more, listed on the interactive page.

Dose: One drop
Route: Topical
How often: Once daily

Administer in the evening
Do not administer more than once daily

Hydrogen bond acceptors: 6
Hydrogen bond donors: 3
Polar surface area: 96.22
Calculated partition coefficient (ALogP): 4.43
Calculated partition coefficient (XLogP): 4.1
Prodrug: Yes
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 1
Rotatable bonds: 12
Heavy atoms: 35
Molecular formula: C26H35F3O6
Monoisotopic mass: 500.23857332
Natural product: No

0078-0946
0378-9651
25021-002
25357-100
42571-130
46708-625
51407-731
62332-510
62332-625
66758-095
68083-601
68083-602
68462-943
70069-586
70069-587
60505-0593
71335-2738
71335-2888
72162-2432

Recorded assays: 45
Active assays: 5

Active assay types

Confirmatory

Antihypertensive Agents
id.nlm.nih.gov

Related records

Trials (102)

1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT
24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
24-Hour Intraocular Pressure (IOP) Control With Travoprost/Timolol Fixed Combination
24-hour Intraocular Pressure Control With Travoprost/Timolol Fixed Combination Versus Travoprost
6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension
A 12 Week Comparison of DuoTrav and Xalacom in Open-Angle Glaucoma
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
A Long-term Safety Study of Once-daily Travatan
A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution
A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension
A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma
A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan
An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Travoprost

Therapeutic areas

Administration routes

Mechanisms of action

Open Targets mechanisms

DrugCentral mechanisms

Active assay types

Related records

Trials (102)

Approved for (3)

In development for (3)

Other linked conditions (1)

Targets (1)

Travoprost

Development status

Names and chemistry

Brand names (12)

Other names (73)

Identifiers

Regulatory information

United States

European Union

Therapeutic areas

Other regulatory facts

Approval status

Pharmacology

Drug classification

Administration routes

Mechanisms of action

Open Targets mechanisms

DrugCentral mechanisms

Investigated indications (4)

Open Targets indications (13)

Reported adverse events (61)

Trial references (44)

Dosing

Conditions of use (2)

Chemical properties

National Drug Codes

Evidence counts

Active assay types

Pharmacologic actions

Related records

Trials (102)

Approved for (3)

In development for (3)

Other linked conditions (1)

Targets (1)